BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PALO ALTO, Calif. and PROVIDENCE, R.I., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genetically driven neurological disorders into potential life-changing medicines for patients.

BridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients

At the start of March, BridgeBio Pharma Inc (NASDAQ: BBIO) won approval for its first drug, fosdenopterin, for sporadic cases of molybdenum cofactor deficiency type A. In the middle of March, it announced positive proof-of-concept data for encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1).

BridgeBio Locks $2B Infigratinib Global Partnership For Oncology Indications

- BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and equally share profits

BridgeBio Pharma's Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

Halozyme Therapeutics

It's worth putting a few of your eggs into this basket if you're worried about a big increase in prices.

Are Biotech Stocks a Good Hedge Against Higher Inflation?

– Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept

BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society's 2021 Annual Meeting

Microsoft

T-Mobile US

Verizon

Comcast

Micron Technology

Procter & Gamble

Sysco

Looking through the 13F reports filed by hedge funds over the past few weeks, it's clear that these investors are betting on technology.

Hedge Fund Buys and Sells: Notable Trends

BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate Origin Biosciences Inc have received the FDA approval for Nulibry (fosdenopterin) Injection to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type-A. MoCD is a rare metabolic disorder characterized by severe and rapidly progressive neurologic damage caused by the functional loss of sulfite oxidase, 1 of 4 molybdenum-dependent enzymes.

BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four years

BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

BridgeBio Pharma (BBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?

–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos' product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET

BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society's 2021 Annual Meeting

Foot Locker

NVIDIA

Petroleo Brasileiro

Delta Air Lines

Alnylam Pharmaceuticals

Whole Earth Brands

Marriott

Papa John's

United Continental Hlds

With the trading day more than halfway over, the broad markets could not make up their mind on a direction.

Delta Air, Foot Locker, Nvidia, Petrobras and More Monday Afternoon Analyst Calls

BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate ML Bio Solutions have dosed the first patient in the Phase 2 trial evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i). LGMD2i is an inherited recessive muscular dystrophy caused by mutation of fukutin-related protein (FKRP), leading to chronic muscle injury and loss, muscle weakness, and disability.

BridgeBio Pharma's BBP-418 Muscular Dystrophy Study Moves Forward With Patient Dosing

SAN FRANCISCO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate ML Bio Solutions today announced that the first patient has been dosed in a Phase 2 trial of BBP-418 in patients with LGMD2i. BridgeBio and ML Bio's BBP-418 is the first-ever oral disease-modifying investigational treatment for LGMD2i. BBP-418 was granted Orphan Drug Designation for LGMD2i by the US Food and Drug Administration (FDA) in 2019, and for LGMD by the European Medicines Agency (EMA) in 2020.

BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

PALO ALTO, Calif. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of 3,000,000 shares of its common stock at a price per share of $62.50 by selling stockholder KKR Genetic Disorder L.P. The selling stockholder has also granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock on the same terms and conditions. All shares are being sold by KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering. The offering is expected to close on February 17, 2021, subject to customary closing conditions.

BridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common Stock

PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The selling stockholder has also granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock. All shares are being sold by KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering.

BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock

PALO ALTO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular anomalies, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of BBP-681 (also known as VT30 Topical Gel).

BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations

BridgeBio recently merged with Eidos, of which it previously owned 64%. AG10 is Eidos' lead asset.

BridgeBio's Eidos Merger And Its Rationale

PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering of $400 million aggregate principal amount of notes. In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $97.5 million aggregate principal amount of notes. The sale of the notes is expected to close on January 28, 2021, subject to customary closing conditions.

BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes

PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $400 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company expects to grant the initial purchasers an option to purchase up to an additional $60 million aggregate principal amount of notes.

BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBio's acquisition of all of the outstanding shares of Eidos common stock that BridgeBio does not already own. The merger is expected to close on or about January 26, 2021, subject to the satisfaction or waiver of other conditions to closing.

Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.

Here's why the biggest biotech IPO of 2019 outshines all its peers.

My Best Biotech Stock for 2021

Editas Medicine

Fate Therapeutics

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

3 Biotech Stocks That Could Double Your Money in 2021

PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio's proposed merger with Eidos and each of the other proposals to be considered at both companies' virtual special meetings to be held on January 19, 2021.

Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger

SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.

UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases

News for BridgeBio Pharma Inc Stock (BBIO)